knowledge -WSS

knowledge

author：explore 2025-09-30 00:38:29 - browse：75963

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： As obesity drug market grows, telehealth companies court payers

entertainment

WSS

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Meadows told special counsel he could not recall Trump ever declassifying Mar

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Meadows told special counsel he could not recall Trump ever declassifying Mar

Hospitals look to new technology to keep health care workers safe

NYU radiologists take on the challenge of expensive MRI machines

leisure time

knowledge

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Trans patients at the end of life deserve respect and dignity

The high cost of giving birth even with insurance

Health officials lay out plans to cope with respiratory virus season

Novavax promises a turnaround & Lilly roils the obesity market

Astellas still sees hope in its gene therapy after four deaths

ChatGPT in medicine: STAT answers readers' burning questions

Can U.S. cancer drug shortages be fixed?

Tori Bowie and the unacceptable rates of Black maternal death

Surge of respiratory disease in China has likely explanation

entertainment

PBM reforms clear House panel

People can get long Covid without testing positive for virus: Study

CDC says it’s too soon to assess risk posed by Covid subvariant

People can get long Covid without testing positive for virus: Study

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

U.K. considers world's first use of meningitis vaccine to address gonorrhea

entertainment

entertainment

hotspot

leisure time